Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Edgewise Therapeutics, Inc.
Next earnings ≈ Aug 6, 2026 · est. from filing cadence
Last earnings -3.8% on 2026-05-07
Conservative balance sheet (liabilities/equity 0.06x).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Edgewise Therapeutics, Inc. shows limited reported revenue, and -32.1% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001710072, latest 10-Q filed 2026-05-07) · EODHD · rules-based read · as of 6/18/2026, 9:01:25 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$43.2M | -$71.7M | -$114M | -$159M | -$191M |
| Net income | -$42.8M | -$67.6M | -$100M | -$134M | -$168M |
| Diluted EPS | -$1.14 | -$1.26 | -$1.57 | -$1.45 | -$1.63 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
Last 90 days: 0 open-market buys · 2 sales
| 2026-05-05 | Donovan Joanne M. CMO | Exercise | 50.0K @ $7.08 | $354K |
| 2026-05-05 | Donovan Joanne M. CMO | Sell | 50.0K @ $38.57 | $1.93M |
| 2026-05-04 | Donovan Joanne M. CMO | Sell | 5.23K @ $31.29 | $164K |
| 2026-04-01 | Fox Jonathan C Director | Award | 339.00 |